Skip to main content
Journal of the Egyptian National Cancer Institute

Table 6 Kaplan-Meier analysis for DFS between the different treatment regimens

From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients

 

Mean DFS

95% CI

Median

95% CI

p value

Endoxan-Dexa

4.444

0.6, 8.3

3

0.0, 11.8

< 0.001*

VCD

29.511

16.4, 42.6

14

6.8, 21.2

VRD

25.613

16.1, 35.2

24

17.5, 30.5

VTD

44.063

24, 64.1

-

-

  1. *Significant at p ≤ 0.05
  2. VCD Velcade® (bortezomib)-cyclophosphamide-dexamethasone, VRD Velcade® (bortezomib)-Revlimid® (lenalidomide)-dexamethasone, VTD Velcade® (bortezomib)-thalidomide-dexamethasone, Endoxan-Dexa endoxan-dexamethasone
Back to article page